Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind, Comparative Study of Micafungin (FK463) Versus Caspofungin as Antifungal Treatment in Patients With Invasive Candidiasis or Candidemia

NCT00105144 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT00105144
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00105144 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind, Comparative Study of Micafungin (FK463) Versus Caspofungin as Antifungal Treatment in Patients With Invasive Candidiasis or Candidemia
Lead sponsor
Astellas Pharma Inc
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2004
Completion date
April 30, 2006
Enrollment
611 (actual)
Sites
167

Conditions

As the registry lists them; a condition with its own page is linked.

candidemia, candidiasis